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Background: In many clinical situations, ordinal scales afford the primary method of semi-quantifying patient
outcomes. In the field of multiple sclerosis, the primary ordinal scale is the Expanded Disability Status Scale.
Predominant methods of ordinal scale statistical analysis provide a p-value without effect size or rely heavily on
the assumption of proportionality of odds, subjecting them to lack of power and error. The Wilcoxon-MannyWhitney Odds is a statistical method which provides significant information such as p-value, effect size, num
ber needed to treat, confidence intervals, and is largely assumption-free. However, its utility has not been
demonstrated in the field of multiple sclerosis.
Methods: Three clinical studies in the field of multiple sclerosis were selected which utilized ordinal scale
outcomes at group or individual levels. Data from these studies was extracted using WebPlotDigitizer, and a
custom Wilxocon-Mann-Whitney Odds software was applied to each dataset to re-analyze the main outcomes of
the studies.
Results: Re-analysis of the manuscript by Muraro et al., 2017 demonstrated that autologous stem cell trans
plantation for relapsing remitting multiple sclerosis resulted in a 65% chance of improving from any Expanded
Disability Status Scale category, although not significant. Re-analysis of the manuscript by Songthammawat
et al., 2019 demonstrated chance of improvement with intravenous methylprednisolone and concurrent plasma
exchange was 185% versus 32% in intravenous methylprednisolone with add-on plasma exchange, although not
significant. Re-analysis of Kister et al., 2012 demonstrated the chances of mobility or cognition scores generally
favored decline at every 5-year increment of study, and although statistically significant, these were smaller
effect sizes ranging from an 11% chance of improvement to a 66% chance of decline over a 5-year interval.
Discussion: The Wilcoxon-Mann-Whitney Odds simplifies ordinal data analysis with its robust largely
assumption-free nature. In the place of numerous statistical tests, this single test provides effect size estimate,
number needed to treat, p-values, and confidence intervals. Importantly, the Wilcoxon-Mann-Whitney Odds
effect size calculation is intuitively applicable to both individual and population-levels. Further, the WilcoxonMann-Whitney Odds allows intuitive description of the progression of large cohorts over time, and we were
able to clearly convey the odds of mobility and cognitive decline over 30 years in a large multiple sclerosis
cohort. Overall, the Wilcoxon-Mann-Whitney Odds is a powerful and robust statistical test with significant
promise within the field of multiple sclerosis.

1. Introduction
The Expanded Disability Status Scale (EDSS) is the most widely used
disability scale in clinical and research settings in multiple sclerosis (MS)

(Kurtzke, 1983). Due to its ordinal nature, the distance between two
consecutive EDSS values is not equivalent (Cumming et al., 2015).
Therefore, much information provided by the EDSS is missed or mis
interpreted when it is analyzed with statistical methods meant for
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Fig. 1. Muraro et al., 2017.

continuous or dichotomic datasets. A common approach in analysis of
EDSS scores is calculation of means, which is statistically inappropriate
given unequal spacing between EDSS scores. Another approach is arti
ficially dichotomizing EDSS values to facilitate statistical analysis which
assumes equivalence of different values within the dichotomized groups,
losing much of the inherent information (Cumming et al., 2015; Howard
et al., 2013).
These limitations have led to the implementation of other methods
for ordinal scale statistical analysis. Among them, the global statistic and
responder analysis have been the most widely used; however, they still
have significant shortcomings (Saver, 2007). Although the global sta
tistic has the benefit of assessesing treatment effects on multiple
outcome measures simultaneously, it fails to translate the measures of
effect from the group level to individual level (Saver, 2007). Responder
analysis addresses ordinal scales by adjusting outcome thresholds to
individual score values at study entry (Saver, 2007). However, this
method requires pre-specifying the variables to be adjusted, which is
often not feasible in practice.
Two other techniques have been proposed to assess the full range of
an ordinal scale. The Cochran–Mantel–Haenszel test is an assumption
free based technique for the analysis of ordinal scales. Since the variance
is derived under the null hypothesis, this method only provides p-values,
without associated effect size estimates (Churilov et al., 2014). The other
method, the proportional-odds logistic regression (also known as ordinal
regression), does provide an intuitive effect size estimate, but its
modeling relies heavily on the assumption of proportionality of odds,
often not satisfied in clinical trials (Williams, 2016).
The “Wilcoxon-Mann-Whitney Odds Ratio”, derived to relax the
proportional odds assumption by Agresti, is an intuitive and statistically
appropriate approach for ordinal data analysis (Agresti, 1980). It should
be noted that this is technically more consistent with an odds than an
odds ratio, and so we note it as the Wilcoxon-Mann-Whitney Odds
(WMW-Odds) (Rahlfs and Zimmerman, 2019). The WMW-Odds method
involves estimation of the odds that a randomly selected subject from
one group will have a better outcome than that of a randomly selected
subject from the other group. In situations wherein probability of a good
outcome is equivalent between the two subjects, the ties may be split in
order to maintain accurate representation. In this study we assessed the
feasibility of implementing the WMW-Odds and its application in Mul
tiple Sclerosis research by re-analysing three relevant published studies
with publicly available data. In this study we aim at assessing the

usability, interpretability and statistical appropriatness of the
WMW-Odds for the analysis of ordinal data, with a particular emphasis
on EDSS data. Altogether, these goals seek to expand on previous con
cerns referred to as “missing medians” (Cumming et al., 2015), or
inaccurate representation of ordinal data in clinical studies (Cumming
et al., 2015).
2. Methods
A Python-based code was developed to apply the WMW-Odds as
follows as follows:
WMW Odds =

[Pr(Y2 > Y1) + 0.5Pr(Y1 = Y2)]
[(Pr(Y2 < Y1) + 0.5Pr(Y1 = Y2)]

This results in the creation of a generalized odds ratio which splits
ties equally across both groups, following a modification of tie handling
for the original Agresti’s Generalized Odds Ratio (Churilov et al., 2014).
To validate the accuracy of the code, the mock data analyzed by Cum
ming et al. was analyzed, and the WMW-O model’s calculated result was
compared to WMW-Odds results calculated manually with Excel calcu
lations (Cumming et al., 2015). Further, a second version of the
WMW-Odds was developed independently of the first by a second in
dependent author using R software. This model’s results were compared
to the Python-based WMW-Odds to assess consistency.
The number needed to treat (NNT), defined as the expected number
of patients who need to be treated such that one patient would have a
better outcome was calculated as:
NNT = 1 +

2
(WMW Odds − 1]

2.1. Characterisitics and re-analysis of studies
Three MS studies implementing different methodologies were
selected. Selection criteria was based on their scientific relevance and
public availability of individual or specific group data (Kister et al.,
2013; Muraro et al., 2017; Songthammawat et al., 2020). When the data
from the studies selected was only available in figures, it was extracted
using WebPlotDigitizer (Rohtagi, 2020).
In the first study Muraro et al. evaluated outcomes after autologous
hematopoietic stem cell transplantation for treatment of relapsing and
progressive forms of multiple sclerosis that failed to respond to standard
2
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Fig. 2. EDSS severity change in patients using IVMP and add on PLEX.

Fig. 3. EDSS severity change in patients using IVMP plus Plex.

therapies (Muraro et al., 2017). Outcomes collected were the EDSS at
baseline and at least one follow-up visit/report after transplantation. For
each patient having an EDSS assessment 1 year before and 1 year after
transplant, the yearly EDSS changes pre- and post-transplant were
calculated and compared by a repeated measures analysis of variance
(ANOVA) with 2 time points (change pre-transplant vs post-transplant).
We re-analyzed the change in EDSS using WMW-Odds in the sub-group
of patients with RRMS, including EDSS change from the first follow up to
the time of the transplant (1,1 +/- 0.16 years prior transplant), from the
time of the transplant to the one year follow up (0.96 +/- 0.19 years
after transplant) and from the time of the transplant to last follow up
(2.3+/- 0.86 years after). In the second study Songthammawat et al.
compared the efficacy between 5 patients with Neuromyelitis Optica
Spectrum Disorders (NMOSD) with a severe acute attack who received
intravenous methylprednisolone (IVMP) with subsequent add-on
plasma exchange (PLEX) versus simultaneous IVMP and PLEX
(Songthammawat et al., 2020). We re-analyzed the change in EDSS for
the same comparisons using WMW-Odds. In the third study Kister et al.
analyzed symptom prevalence in each of the 11 domains included in The
North American Research Committee on Multiple Sclerosis (NARCOMS)
Registry database for the first 30 years from symptom onset, with more

than 35,000 patients recording on symptom from 1996 to June 2011
(Kister et al., 2013). The change over the years was depicted on
“symptom prevalence tables”. We re-analyzed the changes on two
relevant symptoms (mobility and cognition) at 5 years periods during
the 30 years reported.
3. Results
Our comparison of the computational codes developed indepen
dently by two co-authors (SF and JMR) using different software (R and
Python) yielded equal results. In addition, these results were also equal
to those generated by manual calculation and using step-wise analytical
procedures using Excel software. Our re-analysis of the study by Muraro
et al. revealed significant worsening in EDSS from the initial assessment
until the time of transplant while the analysis of EDSS after the trans
plant showed improvement more marked in the first year as compared
with the last follow up, despite not being significant in either case
(Fig. 1) (Muraro et al., 2017). Our re-analysis of the study by Songth
ammawat et al. revealed that treatment effect sizes for the groups using
IVMP plus PLEX and IVMP add-on PLEX did not reach statistical sig
nificance (Figs. 2 and 3) (Songthammawat et al., 2020). The analysis of
3
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Fig. 4. Kister al 2020 Mobility over 30 year.

the study by Kister et al. quantifies the changes in large scale patient
populations over time (Fig. 4 and 5) (Kister et al., 2013).

EDSS changes.
Up to date, most studies utilize mean and standard deviation values
to report EDSS changes (Cumming et al., 2015). However, this approach
is inherently inadequate, as distances between points in ordinal scales
are unevenly spaced. Among different ordinal scales and patients’
populations, this difficulty is particularly notorious when analyzing
EDSS changes, as its distribution is rarely normal, and often follow a
bimodal pattern (Hohol et al., 1995). Muraro et al. suggested significant
mean EDSS increase in people with MS during the 12 months preceding
autologous hematopoietic stem cell transplantation (0.94 points, 95%

4. Discussion
Despite the recent advances in the analysis of neurological scales of
ordinal nature (The optimising Analysis of Stroke Trials (OAST)
Collaboration, 2007), there is yet no general consensus on the most
appropriate statistical method to quantify EDSS changes. In this study
we analyze the features of WMW-Odds, and its feasibility to quantify
4
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Fig. 5. Kister al 2020 Cognition over 30 years.

CI= 0.77 to 1.11), and significant decrease following the transplant
(0.32, 95%CI= − 0.15 to − 0.49) (Muraro et al., 2017). Our re-analysis
demonstrated that the chances for patients with RRMS to improve
from any given EDSS category to a better category at one year after the
transplant were 1.65 or 65% over the first year and 1.49 or 49% at the
last follow up (Fig. 1). Our analysis yielded statistically significant EDSS
worsening before entering the study, but only a tendency for improve
ment for the 1 year and last follow up (p = 0.09 and 0.17). These sta
tistical outcomes are likely limited by the retrospective nature of the
study. Similarly, our analysis of the study by Songthammawat et al.

indicated similar trends to those suggested by the authors, however,
statistical significance was not reached (Fig. 2 and 3) (Songthammawat
et al., 2020). Similar to the initial study, the power of the study was
largely limited by its small sample size, and limited by its retrospective
nature. However, we also believe that the inaccurate impression of
statistical significance in the original results was caused by the unfitted
statistical approach. This could in turn hamper proper design of future
studies (i.e. inaccurate sample size calculation). Nevertheless, it should
not be assumed that WMW-Odds is less likely to detect significant
treatment effects than parametric analyses. On the contrary, the
5
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experience using other common ordinal scales (i.e. Rankin scale), has
demonstrated that parametric and binary outcomes analysis are often
less likely to detect significant treatment effects in the context of
non-parametric distributions (The Optimising Analysis of Stroke Trials
(OAST) Collaboration, 2007).
The use of WMW-Odds could be advantageous in the context of large
sample sizes. In this circumstance, the analysis of statistical significance
alone can be misleading, and the use of appropriate effect size estima
tion aids in the interpretation of clinical relevance of an effect. Kister
et al. assessed the natural history of large MS cohorts, rounding 35,000
patients per cohort, and were able to discern 2 divergent patterns of
progression among different symptoms. While in domains such as
mobility a steady worsening was observed over the 3 decades of follow
up, other domains such as cognition demonstrated little change in the
distribution after the initial 15 years of disease. However, the authors
only used a visual inspection of their “symptom prevalence tables”,
without any statistical analysis, only reporting the percentage of change
within the groups. Our re-analysis of these two domains (mobility and
cognition) implementing WMW-Odds allowed quantifying the change
for the patterns observed by Kister et al. (Fig. 4) (Kister et al., 2013). For
example, the chance of progressing to a worse category of mobility
during the first 5 years of enrollment was 66% (WMW-Odds=1.66), and
despite the progression was slower over the following decades, a size
able worsening was still observed over the last 5 years of the analysis
(WMW-Odds=1.23) (Fig. 4). On the contrary, this pattern was not
observed in the cognition domain, where worsening was markedly
reduced towards last years of follow-up. Regarding the underlying data,
a recent study demonstrated 15% of the population in this patient cohort
had passed away by 2010, which raises concern for possible frame shifts
which may obscure changes in symptoms severity over time by masking
changes in patients who passed away (Cutter et al., 2015).
WMW-Odds also enables the estimation of NNT. NNT, defined as the
expected number of people who need to be treated for one person to
benefit, has an immediate natural relationship to WMW-Odds as previ
ously described (Bath et al., 2011). Specifically, this is a net NNT, which
contrasts the odds that a person receiving a given treatment or inter
vention improves, remains the same, or declines, compared to someone
not receiving it. NNT are thought to be generally lower when imple
menting ordinal approaches, such as WMW-Odds, as compared to binary
approaches. This higher sensitivity has been demonstrated by analysing
ordinal outcomes from stroke trials, and a similar effect may be expected
for trials analyzing EDSS changes. Our calculations of NNT provided
complementary insight into the effect sizes for the comparisons (Figs. 1,
4 and 5).
In addition, the use of WMW-Odds allows pooling of ordinal out
comes in meta-analysis using the standard analytical approach for odds
ratios (Churilov et al., 2014). The current lack of standard ordinal
analysis, might lead to exclusion of MS studies from metanalysis
(Cumming et al., 2015). Conversely, as meta-analyses are heavily
influenced by assumption of normality, dichotomizing ordinal outcomes
is not a feasible alternative. Cumming et al. demonstrated that
WMW-Odds can be readily combined in meta-analysis, and stated that it
is not be limited to ordinal data, but could also be applied to continuous
data (Cumming et al., 2015). Importantly, with simple ordinal tables, a
synthetic individual-level dataset can be created and analyzed using the
WMW-Odds, allowing analysis of synthetic individual-level data from
meta-analysis data.
Overall, the WMW-Odds is a relatively easily computed odds ratio.
Being similar to proportional odds models, WMW-Odds does not rely
upon the assumption of proportional odds, and therefore its application
is not subject to undesirable test-born premises restricting the inter
pretability of the results(Howard et al., 2013). Nevertheless, this
advantage is not in detriment of losing other benefits of proportional
odds models, such as the possibility of adjusting for covariates. Despite
this particular aspect is not explored in this paper due to the unavail
ability of individual covariates data in the studies examined, this

characteristic has been explicitly demonstrated by Howard et al.
(Howard et al., 2013), and we believe it represents a venue for further
research.
This study has some limitations. First, extracting individual data
from published figures in addition to tables and text provided by the
publications might have led to discrepancies. In addition, comparison of
effect sizes using the WMW-Odds approach vs. dichotomization of EDSS
outcomes was not conducted in this study. Lastly, our study did not
collect sufficient data to test the use of WMW-Odds outcomes in
metanalysis.
In conclusion, our study demonstrated that WMW-Odds is a conve
nient and straightforward statistical approach to analyze and report
EDSS changes. WMW-Odds provides an assumption-free and easy to
compute effect size estimation, that can be implemented in multiple
study designs, and can be readily combined in meta-analysis. The use of
WMW-Odds might specially benefit progressive MS research, where
outcomes are typically based on EDSS. Specifically, the WMW-Odds
improves the analysis of EDSS data by respecting the ordinal nature of
EDSS data, without compromising its robustness as a statistical tool
(Cumming et al., 2015). In the future, it should be tested whether uti
lizing WMW-Odds improves the detection of significant effects, as it
could allow to decrease the sample sizes required in clinical research.
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